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although the biology of Def6 may be
complex, it is hard for us to see how it
could be a negative regulator of IL-17 in
Def6trap/trap DO11.10 mice and, at the
same time, a positive regulator of IL-17
in Def6/ C57BL/6 mice (unless, of
course, the DO11.10 transgene expres-
sion resulted in an artifact).
We are also concerned about other
data presented in the study by Chen
et al. (2008). As the authors show (Figure 4
of Chen et al. [2008]), and consistent with
other published reports (Ivanov et al.,
2006; Yang et al., 2008) and our own
experience, in vitro stimulation of naive
CD4+ T cells with CD3 and CD28
antibodies in the absence of antigen-
presenting cells or the prerequisite Th17
cell-polarizing cytokines (defined as Th0
conditions by Chen et al. [2008]) fails
to induce substantial IL-17 expression.
However, Figure 7A of the same paper
shows substantial IL-17 expression
by wild-type C57BL/6 mice cultured
under Th0 conditions, which is intrinsi-
cally inconsistent with the data in Fig-
ure 4A, as well as with other published
studies.
In summary, we have doubts about
whether studies documenting enhanced
susceptibility of Def6/mice to systemic
autoimmunity and inflammation (Chen
et al., 2008; Fanzo et al., 2006) reflect
the true biology of Def6, given obvious
issues related to the genetic background
of the mice used in these studies.
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DOI 10.1016/j.immuni.2009.06.012We are glad to have the opportunity to
clarify the points that Drs. Altman and Be´-
cart have raised regarding our manu-
script. Because Def6 is the official name
of the gene, we will henceforth use this
nomenclature rather than its alternate
names, IBP and SLAT.
Gene deletion that leads to autoimmu-
nity such as lupus-like syndrome occur
only in selected strains of mice because
the development of autoimmunity usually
requires interaction of the effects of the
single gene deletion with those mediated
by various strain-specific background
loci (Jorgensen et al., 2004). We were
thus not surprised to observe, as Altman
and Be´cart have, that Def6trap/trap mice
on a C57BL/6 background do not develop2 Immunity 31, July 17, 2009 ª2009 Elseviera lupus-like syndrome. We have, how-
ever, observed that CD4+ T cells from
Def6trap/trap mice backcrossed onto either
a C57BL/6 or a BALB/c background (for >
10 generations) always exhibit deregu-
lated expression of IL-17 and IL-21 under
neutral conditions in vitro (although the
absolute amounts can vary depending
on the strain). Furthermore, deregulated
expression of IL-17 and IL-21 can be
observed in both transgenic (DO11.10)
and nontransgenic Def6trap/trap T cells,
indicating that this effect is not due to an
artifact imposed by the DO11.10 trans-
gene. For these reasons, we have felt
comfortable using CD4+ T cells from
Def6trap/trap mice on either a C57BL/6 or
a BALB/c background in our manuscript.Inc.We believe that this is a strength of the
system rather than a concern because
the presence of similar abnormalities in
CD4+ T cells from Def6trap/trap mice from
multiple strains strongly supports the
idea that this defect is truly due to the
absence of Def6 and not to the presence
of strain-specific modifiers (or to the pres-
ence of the DO11.10 transgene). Further-
more, our data on the role of Def6 on the
productionof IL-17and IL-21werebacked
by substantial mechanistic studies, which
could not have been influenced by the
strain background of our mice. In partic-
ular, these studies linked Def6 to the
regulation of interferon-regulatory factor-4
(IRF-4), a transcription factorwhose role in
the regulation of IL-17 and IL-21 has been
Immunity
Lettersindependently corroborated (Brustle et al.,
2007; Huber et al., 2008). We would not
have been able to obtain all these mecha-
nistic insights if we were solely dealing
with epistatic interactions between the
129 and C57BL/6 strains.
As discussed in our manuscript (Chen
et al., 2008), although the absence of
Def6 leads T cells to aberrantly produce
IL-17 and IL-21 under neutral conditions
in vitro, the ability of this abnormality to
lead to pathophysiology in vivo will only
be unmasked in the presence of addi-
tional interactions. This is where strain-
specific modifiers (or the DO11.10 trans-
gene as discussed) play a role. We believe
that this situation, where multiple genes
need to cooperate to unleash the patho-
genic predisposition in vivo, is reflective
of the pathophysiology seen in human
autoimmunedisorders.Wewould also like
to stress that the development of lupus-
like syndromes by many single-gene
deficiencies (even on a mixed 129-BL6
strain) has provided important information
regarding pathways, which are altered in
patients with autoimmunity (Jorgensen
et al., 2004). The importance of our work
thus goes beyond Def6 per se because it
suggests that abnormalities in pathways
regulating IRF-4 may play a role in the
development of autoimmunity. Indeed, we
have recently found that abnormalities in
IRF-4 function can be detected in T cells
from other spontaneous mouse models of
autoimmunity such asMRL/lprmice. Obvi-
ously, more studies will be needed to
corroborate this notion but discounting
the potential role of the Def6-IRF4 pathway
in autoimmunity seems premature.
Regarding the concern with DO11.10
transgene, we believe the disease results
from the enhanced potency by which the
DO11.10 T cell receptor (TCR), in the
absence of Def6, recognizes self-
peptides presented in the context of
I-Ad. Thus, we are not surprised that
Def6trap/trap OT-II mice do not develop
a similar disease to Def6trap/trap DO11.10
mice because presentation of peptides
to the OT-II TCR in these mice occurs in
the context of I-Ab, which may not be
able to present the same self-peptides
and/or result in the same degree of
heightened responses by the OT-II TCR
compared to the DO11.10 TCR. Indeed,
although the DO11.10 TCR and the OT-II
TCR recognize the same core epitope of
the OVA peptide, their ability to recognizesecondary TCR contact residues and
peptide-flanking residues differs (Robert-
son et al., 2000). We thus believe that
not all TCRs can lead to pathophysiology
in the absence of Def6 and that this effect
may be restricted to TCRs in which the
lack of Def6 ‘‘tips’’ the balance toward
T cell activation. Testing this possibility
will require crossing the Def6trap/trap mice
to a large number of TCR-transgenic
mice in different genetic backgrounds. In
support of our idea that the pathophysi-
ology observed in Def6trap/trap DO11.10
mice is due to a dual effect of alterations
in TCR responsiveness and effector func-
tion, we have found that the deregulated
expressionof IL-17and IL-21bynontrans-
genic Def6trap/trap T cells is augmented by
repetitive stimulation. Understanding the
relationship between the antigen speci-
ficity of the T cells and the putative self-
antigen(s) that elicits the autoimmune-
like inflammatory response will require
the identification of the self-antigen(s).
Similar to Altman and Be´cart, we have
also found that the lack of Def6 renders
mice less susceptible to experimental
autoimmune encephalomyelitis (EAE).
However, we do not believe that such
a result invalidates the findings in
Def6trap/trap DO11.10 mice. Although
both the pathophysiology observed in
Def6trap/trap DO11.10 and that ob-
served in EAE involve IL-17-producing
T cells, these two models are drastically
different. Indeed, although the arthritis
in Def6trap/trap DO11.10 mice develops
spontaneously in the absence of strong
inflammatory stimuli, EAE is an induced
model of autoimmunity, which requires
immunization with complete Freund’s
adjuvant, i.e., a strong inflammatory
milieu. As we have stated in our manu-
script, the aberrant IL-17 and IL-21
production by Def6trap/trap T cells occurs
under neutral conditions, i.e., in the
absence of an inflammatory milieu. We
favor the possibility that these are T helper
0 (Th0) cells that have only acquired a
partial Th17 cell program and that this
may actually further contribute to the
pathophysiology because the regulatory
loops that may be in place in ‘‘fully differ-
entiated’’ Th17 cells to control their func-
tion may not be operative in these
‘‘partially differentiated Th17-like’’ cells.
In support of this idea, in vitro Th17 cell
differentiation occurs rather normally in
the absence of Def6. We thus suspectImmuthat although Def6 controls IRF-4 function
under Th0 cell conditions, its ability to
inhibit IRF-4 will be blocked upon expo-
sure to a Th17 cell-inducing inflammatory
milieu. Thus, the effects of Def6 defi-
ciency on IL-17-mediated autoimmune
responses will vary depending on the
precise pathway that has gone awry.
Regarding the production of IL-17 in
Figure 7A versus that in Figure 4A (Chen
et al., 2008), the scales of the two figures
are different because of the presence of
Th17 cell-skewing conditions in Figure 4A.
This may lead to over-interpretation of the
magnitude of discrepancy between the
two figures. We do not believe there is
a significant difference between the two
figures, and any differences in baseline
IL-17 production may be due to the
different purification methods. Neverthe-
less, it does not invalidate the key point
of Figure 7A, which is to demonstrate
that concomitant lack of IRF-4 can abolish
any aberrant production of IL-17 and IL-21
detected in the absence of Def6.
In summary, we believe that our study
provides new insights into the pathophys-
iology of autoimmune disorders. As for
many other molecules, much more work
will be required to fully understand the
role of Def6 in autoimmunity. We became
involved in characterizing Def6-depen-
dent pathways because of our interest in
IRF-4,whichhascomplex regulatory func-
tions. We thus expect the biology of Def6
to exhibit an even more complex role in
T cell physiology and pathophysiology
given its additional effects on cytoskeletal
reorganization, NFAT (Be´cart et al., 2008),
and other targets.
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